Cargando…

Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis

Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both...

Descripción completa

Detalles Bibliográficos
Autores principales: Jocius, Donatas, Vajauskas, Donatas, Mikelis, Kipras, Jokubauskiene, Skirmante, Jakutiene, Jolita, Strupas, Kestutis, Tamosiunas, Algirdas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612220/
https://www.ncbi.nlm.nih.gov/pubmed/36295494
http://dx.doi.org/10.3390/medicina58101333
_version_ 1784819720445231104
author Jocius, Donatas
Vajauskas, Donatas
Mikelis, Kipras
Jokubauskiene, Skirmante
Jakutiene, Jolita
Strupas, Kestutis
Tamosiunas, Algirdas E.
author_facet Jocius, Donatas
Vajauskas, Donatas
Mikelis, Kipras
Jokubauskiene, Skirmante
Jakutiene, Jolita
Strupas, Kestutis
Tamosiunas, Algirdas E.
author_sort Jocius, Donatas
collection PubMed
description Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both invasive and noninvasive techniques are used in the diagnosis and staging of chronic liver impairment. Those techniques include liver biopsy, multiple serological markers (as either single tests or combined panels), and imaging examinations, such as ultrasound or magnetic resonance elastography. Nuclear medicine probes may also be employed in staging liver fibrosis, although the literature scarcely reports this. The purpose of our study was to investigate whether a dynamic liver scintigraphy with [(99m)Tc]Tc-mebrofenin has any value in staging or grading chronic liver damage. Materials and Methods—We prospectively enrolled patients with chronic viral hepatitis B and C infection referred for liver biopsy. All patient underwent dynamic liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy. Dynamic liver scintigraphy was performed immediately after intravenous tracer injection for 30 min scanning time. Multiple scintigraphy parameters were calculated (whole liver lobe and focal area time to peak (TTP), 30 min to peak ratio (30/peak), whole lobe and focal area slope index in 350 s (slope_350). Liver biopsy took place shortly after imaging. Results—We found that many dynamic scintigraphic parameters are positively or negatively associated with different stages of liver fibrosis. The main parameters that showed most value are the ratio between 30 min and the peak of the dynamic curve (30/peak_dex (ratio)), and liver clearance corrected for body surface area and liver area (LCL_m(2)_dm(2) (%/min/m(2)/dm(2))). Conclusions—Our present study proves that conducting dynamic liver scintigraphies with [(99m)Tc]Tc-mebrofenin has potential value in staging liver fibrosis. The benefits of this method, including whole liver imaging and direct imaging of the liver function, provide an advantage over presently used quantitative imaging modalities.
format Online
Article
Text
id pubmed-9612220
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96122202022-10-28 Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis Jocius, Donatas Vajauskas, Donatas Mikelis, Kipras Jokubauskiene, Skirmante Jakutiene, Jolita Strupas, Kestutis Tamosiunas, Algirdas E. Medicina (Kaunas) Article Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both invasive and noninvasive techniques are used in the diagnosis and staging of chronic liver impairment. Those techniques include liver biopsy, multiple serological markers (as either single tests or combined panels), and imaging examinations, such as ultrasound or magnetic resonance elastography. Nuclear medicine probes may also be employed in staging liver fibrosis, although the literature scarcely reports this. The purpose of our study was to investigate whether a dynamic liver scintigraphy with [(99m)Tc]Tc-mebrofenin has any value in staging or grading chronic liver damage. Materials and Methods—We prospectively enrolled patients with chronic viral hepatitis B and C infection referred for liver biopsy. All patient underwent dynamic liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy. Dynamic liver scintigraphy was performed immediately after intravenous tracer injection for 30 min scanning time. Multiple scintigraphy parameters were calculated (whole liver lobe and focal area time to peak (TTP), 30 min to peak ratio (30/peak), whole lobe and focal area slope index in 350 s (slope_350). Liver biopsy took place shortly after imaging. Results—We found that many dynamic scintigraphic parameters are positively or negatively associated with different stages of liver fibrosis. The main parameters that showed most value are the ratio between 30 min and the peak of the dynamic curve (30/peak_dex (ratio)), and liver clearance corrected for body surface area and liver area (LCL_m(2)_dm(2) (%/min/m(2)/dm(2))). Conclusions—Our present study proves that conducting dynamic liver scintigraphies with [(99m)Tc]Tc-mebrofenin has potential value in staging liver fibrosis. The benefits of this method, including whole liver imaging and direct imaging of the liver function, provide an advantage over presently used quantitative imaging modalities. MDPI 2022-09-23 /pmc/articles/PMC9612220/ /pubmed/36295494 http://dx.doi.org/10.3390/medicina58101333 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jocius, Donatas
Vajauskas, Donatas
Mikelis, Kipras
Jokubauskiene, Skirmante
Jakutiene, Jolita
Strupas, Kestutis
Tamosiunas, Algirdas E.
Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title_full Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title_fullStr Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title_full_unstemmed Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title_short Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
title_sort quantitative assessment of liver impairment in chronic viral hepatitis with [(99m)tc]tc-mebrofenin: a noninvasive attempt to stage viral hepatitis-associated liver fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612220/
https://www.ncbi.nlm.nih.gov/pubmed/36295494
http://dx.doi.org/10.3390/medicina58101333
work_keys_str_mv AT jociusdonatas quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT vajauskasdonatas quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT mikeliskipras quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT jokubauskieneskirmante quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT jakutienejolita quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT strupaskestutis quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis
AT tamosiunasalgirdase quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis